CA Patent

CA2470612A1 — Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5

Assigned to Merck and Co Inc · Expires 2003-07-03 · 23y expired

What this patent protects

Imidazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, a re mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, de…

USPTO Abstract

Imidazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, a re mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder a nd panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.

Drugs covered by this patent

Patent Metadata

Patent number
CA2470612A1
Jurisdiction
CA
Classification
—
Expires
2003-07-03
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.